US89422G1076
US89422G1076
Travere Therapeutics, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 4.85B EUR | 5.35B EUR | 2.75B EUR | 3.47B EUR |
Enterprise Value | 5.03B EUR | 5.85B EUR | 2.99B EUR | 3.71B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | 221.57x |
Forward P/E | 9.24x | -- | -- | -- |
Price to Sales | 8.2x | 9.05x | 5.12x | 8.49x |
Price to Book | 200.48x | 218.17x | 27.81x | 30.26x |
EV/Revenue | 8.51x | 9.89x | 5.58x | 9.07x |
EV/EBITDA | 219.66x | 1,012.33x | 77.71x | 77.7x |
Price to FCF (P/FCF) | -- | 352.81x | -- | 103.38x |
EV/FCF | -- | 385.73x | -- | 110.4x |
FCF Yield | -0.38% | 0.28% | -1.05% | 0.97% |